

Ocular Therapeutix™ to Participate in Two Upcoming Investor Conferences

February 19, 2015

BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 19, 2015-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences:

- RBC Capital Markets Healthcare Conference Tuesday, February 24, 2015 at 11:00 a.m. Eastern Time The New York Palace Hotel, New York, NY
- Cowen and Company 35th Annual Health Care Conference Wednesday, March 4, 2015 at 10:40 a.m. Eastern Time The Boston Marriott Copley Place Hotel, Boston, MA

A live audio webcast of the presentations can be accessed through the Calendar of Events section of the Company's website at investors.ocutx.com. A replay of the webcasts will be available on the Company's website for two weeks following the presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma, allergic conjunctivitis, and dry eye disease. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Source: Ocular Therapeutix, Inc.

Investors:

Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
bsmith@ocutx.com
or
Burns McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich, 212-213-0006
kminarovich@burnsmc.com
or

Media:

Scott Corning
Vice President of Sales and Marketing
scorning@ocutx.com